Blueprint Medicines Corp (BPMC)
90.69
+3.84
(+4.42%)
USD |
NASDAQ |
Apr 22, 16:00
90.69
0.00 (0.00%)
After-Hours: 20:00
Blueprint Medicines Total Assets (Quarterly): 1.049B for Dec. 31, 2023
Total Assets (Quarterly) Chart
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.049B |
| September 30, 2023 | 1.105B |
| June 30, 2023 | 1.106B |
| March 31, 2023 | 1.220B |
| December 31, 2022 | 1.350B |
| September 30, 2022 | 1.458B |
| June 30, 2022 | 1.192B |
| March 31, 2022 | 1.143B |
| December 31, 2021 | 1.252B |
| September 30, 2021 | 1.477B |
| June 30, 2021 | 1.569B |
| March 31, 2021 | 1.625B |
| December 31, 2020 | 1.718B |
| September 30, 2020 | 1.558B |
| June 30, 2020 | 817.46M |
| March 31, 2020 | 913.62M |
| December 31, 2019 | 707.69M |
| September 30, 2019 | 737.92M |
| June 30, 2019 | 807.18M |
| Date | Value |
|---|---|
| March 31, 2019 | 544.66M |
| December 31, 2018 | 540.12M |
| September 30, 2018 | 606.11M |
| June 30, 2018 | 665.11M |
| March 31, 2018 | 664.47M |
| December 31, 2017 | 715.74M |
| September 30, 2017 | 420.12M |
| June 30, 2017 | 444.72M |
| March 31, 2017 | 252.65M |
| December 31, 2016 | 282.80M |
| September 30, 2016 | 167.85M |
| June 30, 2016 | 186.52M |
| March 31, 2016 | 206.01M |
| December 31, 2015 | 178.90M |
| September 30, 2015 | 195.29M |
| June 30, 2015 | 204.21M |
| March 31, 2015 | 55.91M |
| December 31, 2014 | 49.92M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
707.69M
Minimum
Dec 2019
1.718B
Maximum
Dec 2020
1.201B
Average
1.192B
Median
Jun 2022
Total Assets (Quarterly) Benchmarks
| Alnylam Pharmaceuticals Inc | 3.830B |
| Apellis Pharmaceuticals Inc | 788.73M |
| Ionis Pharmaceuticals Inc | 2.990B |
| Madrigal Pharmaceuticals Inc | 640.55M |
| Sarepta Therapeutics Inc | 3.265B |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 918.64M |
| Shareholders Equity (Quarterly) | 130.61M |
| Debt to Equity Ratio | 1.828 |
| Current Ratio | 3.761 |
| Net Debt Paydown Yield | -0.36% |